YAP1 and breast neoplasm: Under the same conditions, the ROCK inhibitor had little if any effect on in vivo growth of HCC1395 breast tumor cells harboring a p53 conformational mutant and lacking detectably elevated TEAD/YAP transcription (Fig. 5b).